Carol D. Morris

Carol D. Morris

Auto-generated profile, based on publicly available information

Carol D. Morris

Memorial Sloan Kettering Cancer Center 2 Department of Orthopedic Surgery New York, New York

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of the American Academy of Orthopaedic Surgeons
Verified
Journal Article
Closed access
ALAlexander E. Loeb
Alexander E. Loeb
SRSandesh S. Rao
Sandesh S. Rao
JFJames R. Ficke
James R. Ficke
CMCarol D. Morris
Carol D. Morris
LRLee H. Riley
Lee H. Riley
ALAdam S. Levin
Adam S. Levin
Despite the use of digital technology in healthcare, telemedicine has not been readily adopted. During the COVID-19 pandemic, healthcare systems have begun crisis management planning. To appropriately allocate resources and prevent virus exposure while maintaining effective patient care, our orthopaedic surgery department rapidly introduced a robust telemedicine program during a 5-day period. Implementation requires attention to patient triage, technological resources, credentialing, education of providers and patients, scheduling, and regulatory considerations. This article provides practical instruction based on our experience for physicians who wish to implement telemedicine during the COVID-19 pandemic. Between telemedicine encounters and necessary in-person visits, providers may be able to achieve 50% of their typical clinic volume within 2 weeks. When handling the massive disruption to the routine patient care workflow, it is critical to understand the key factors associated with an accelerated introduction of telemedicine for the safe and effective continuation of orthopaedic care during this pandemic. Level of Evidence: V

24 April 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LCLingling Chen
Lingling Chen
TOTeniola Oke
Teniola Oke
NSNicholas Siegel
Nicholas Siegel
GCGady Cojocaru
Gady Cojocaru
ATAda J. Tam
Ada J. Tam
NLNicolas J Llosa
Nicolas J Llosa
Purpose: Clinical trials with immune checkpoint inhibition in sarcomas have demonstrated minimal response. Here, we interrogated the tumor microenvironment (TME) of two contrasting soft-tissue sarcomas (STS), rhabdomyosarcomas and undifferentiated pleomorphic sarcomas (UPS), with differing genetic underpinnings and responses to immune checkpoint inhibition to understand the mechanisms that lead to response. Experimental Design: Utilizing fresh and formalin-fixed, paraffin-embedded tissue from patients diagnosed with UPS and rhabdomyosarcomas, we dissected the TME by using IHC, flow cytometry, and comparative transcriptomic studies. Results: Our results demonstrated both STS subtypes to be dominated by tumor-associated macrophages and infiltrated with immune cells that localized near the tumor vasculature. Both subtypes had similar T-cell densities, however, their in situ distribution diverged. UPS specimens demonstrated diffuse intratumoral infiltration of T cells, while rhabdomyosarcomas samples revealed intratumoral T cells that clustered with B cells near perivascular beds, forming tertiary lymphoid structures (TLS). T cells in UPS specimens were comprised of abundant CD8+ T cells exhibiting high PD-1 expression, which might represent the tumor reactive repertoire. In rhabdomyosarcomas, T cells were limited to TLS, but expressed immune checkpoints and immunomodulatory molecules which, if appropriately targeted, could help unleash T cells into the rest of the tumor tissue. Conclusions: Our work in STS revealed an immunosuppressive TME dominated by myeloid cells, which may be overcome with activation of T cells that traffic into the tumor. In rhabdomyosarcomas, targeting T cells found within TLS may be key to achieve antitumor response.

1 January 2003 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CMCarol D. Morris
Carol D. Morris
KSKent Sepkowitz
Kent Sepkowitz
CFClaudette Fonshell
Claudette Fonshell
NMNeil Margetson
Neil Margetson
JEJanet Eagan
Janet Eagan
JHJohn Healey
John Healey

1 July 2005 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
PDF file
CMCarol D. Morris
Carol D. Morris
TEThomas A. Einhorn
Thomas A. Einhorn
Bisphosphonates are the most clinically important class of antiresorptive agents available to treat diseases characterized by osteoclast-mediated bone resorption. Currently, seven bisphosphonates have the approval of the United States Food and Drug Administration. The most common adult diseases treated with bisphosphonates include osteoporosis, Paget disease, and metastatic bone disease. The treatment of pediatric disorders such as osteogenesis imperfecta and fibrous dysplasia with bisphosphonates has gained momentum, and initial investigations have demonstrated an acceptable safety profile. Currently, there is a lack of long-term follow-up data, which will be necessary for the development of responsible guidelines for therapy.

1 September 2018 in Surgical Oncology
Verified
Journal Article
Closed access
ALAndrew D. Lynch
Andrew D. Lynch
FGFaiz Gani
Faiz Gani
CMChristian F. Meyer
Christian F. Meyer
CMCarol D. Morris
Carol D. Morris
NANita Ahuja
Nita Ahuja
Fabian M. JohnstonFabian M. Johnston
Fabian M. Johnston

1 June 2008 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Open access
PDF file
JSJoseph H. Schwab
Joseph H. Schwab
CACristina R. Antonescu
Cristina R. Antonescu
EAEdward A. Athanasian
Edward A. Athanasian
PBPatrick J. Boland
Patrick J. Boland
JHJohn Healey
John Healey
CMCarol D. Morris
Carol D. Morris
While low-grade juxtacortical and low-grade intramedullary osteogenic sarcomas are histologically indistinguishable, they have been studied as separate entities. We retrospectively reviewed the clinical, radiographic, histologic features and treatment of 59 patients treated surgically to compare the rate of local recurrence, grade progression, and survival between low-grade intramedullary and low-grade juxtacortical osteogenic sarcoma. Forty-five (76%) patients were treated for low-grade juxtacortical osteogenic sarcoma and 14 (24%) were treated for low-grade intramedullary osteogenic sarcoma. Local recurrence rates of 7% were similar for both groups studied. The rate of distant metastases was also similar for both groups. . The rate of dedifferentiation for the entire group was 29%. Dedifferentiated lesions were treated with adjuvant chemotherapy in 16 of 17 cases. Recurrence preceded dedifferentiation in four cases. Five-year survival was over 90% in both groups. Low-grade intramedullary and low-grade juxtacortical osteogenic sarcoma were clinically indistinguishable with identical rates of local recurrence, distant metastases, dedifferentiation, and survival. Level of Evidence: Level III, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.